Literature DB >> 22740183

Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature.

Francesco Dentali1, Anna Paola Sironi, Walter Ageno, Sara Turato, Carlo Bonfanti, Francesco Frattini, Silvia Crestani, Massimo Franchini.   

Abstract

It is well known that the ABO blood group exerts a major influence on hemostasis, as O blood group individuals have lower von Willebrand factor and factor VIII levels than non-O blood group subjects. To evaluate the possible clinical implication of the different ABO blood groups on the risk of developing venous thromboembolism (VTE), we conducted a meta-analysis of the existing literature. After an electronic search strategy using Medline and Embase and a manual review of abstract books of the International Society on Thrombosis and Haemostasis and of reference lists of all retrieved articles, we included in the systematic review 38 studies with 10,305 VTE cases. The prevalence of non-O blood group was significantly higher in VTE patients compared with controls with a resulting pooled odds ratio (OR) of 2.09 (95% confidence interval [CI], 1.83, 2.38; p < 0.00001). Similar findings were obtained when the genotypes A1O/BO/A2B (OR 1.73, 95% CI, 1.47, 2.05; p < 0.00001) and A1B/A1A1/BB (OR 1.87, 95% CI, 1.84, 2.44; p < 0.00001) were analyzed. The maximum VTE risk was observed in non-O-factor V Leiden patients (OR 7.60, 95% CI, 3.21, 17.99), while for G20210A prothrombin mutation it was not possible to perform a pooled analysis due to a paucity of published studies. Finally, the association between non-O blood group and VTE was weaker when provoked VTE cases were considered (OR 1.33, 95% CI, 1.18, 1.50), while it was substantially unchanged when unprovoked VTE cases were analyzed (OR 1.88, 95% CI, 1.42, 2.50). In conclusion, considering its prevalence, non-O blood group is a candidate to be one of the most important genetic risk factors for venous thrombosis. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740183     DOI: 10.1055/s-0032-1315758

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  68 in total

Review 1.  Multifaceted role of glycosylation in transfusion medicine, platelets, and red blood cells.

Authors:  Melissa M Lee-Sundlov; Sean R Stowell; Karin M Hoffmeister
Journal:  J Thromb Haemost       Date:  2020-05-28       Impact factor: 5.824

Review 2.  Beyond immunohaematology: the role of the ABO blood group in human diseases.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

3.  ABO blood group and risk of peripheral arterial thrombosis in patients with atrial fibrillation: a single center survey.

Authors:  Massimo Franchini; Chiara Rossi; Francesco Frattini; Silvia Crestani; Cinzia Sissa; Moreno Meschieri; Ivano Giacomini; Mario Luppi; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

4.  ABO blood group and fertility: a single-centre study.

Authors:  Carlo Mengoli; Carlo Bonfanti; Chiara Rossi; Massimo Franchini
Journal:  Blood Transfus       Date:  2015-04-27       Impact factor: 3.443

5.  Impact of sickle cell trait on the thrombotic risk associated with non-O blood groups in northern Nigeria.

Authors:  Sagir G Ahmed; Modu B Kagu; Umma A Ibrahim; Audu A Bukar
Journal:  Blood Transfus       Date:  2015-05-27       Impact factor: 3.443

6.  Blood group distribution and life-expectancy: a single-centre experience.

Authors:  Carlo Mengoli; Carlo Bonfanti; Chiara Rossi; Massimo Franchini
Journal:  Blood Transfus       Date:  2014-10-29       Impact factor: 3.443

7.  ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?

Authors:  Natália Mastantuono Nascimento; Sergio Paulo Bydlowski; Rosangela Paula Silva Soares; Danieli Castro Oliveira de Andrade; Eloísa Bonfá; Luciana Parente Costa Seguro; Eduardo Ferreira Borba
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

8.  O blood group is a risk factor for severe mucosal hemorrhage in orally anticoagulated patients.

Authors:  Massimo Franchini; Chiara Rossi; Carlo Mengoli; Moreno Meschieri; Francesco Frattini; Silvia Crestani; Ivano Giacomini; Mario Luppi; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

Review 9.  ABO blood group and risk of coronary artery disease.

Authors:  Massimo Franchini; Chiara Rossi; Carlo Mengoli; Francesco Frattini; Silvia Crestani; Ivano Giacomini; Mario Luppi; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

10.  ABO blood group influences transfusion and survival after cardiac surgery.

Authors:  Ian J Welsby; Barbara Phillips-Bute; Joseph P Mathew; Mark F Newman; Richard Becker; Sunil Rao; Carmelo A Milano; Mark Stafford-Smith
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.